Using related bromodomain inhibitor and PROTAC compounds (that is, GNE-049 and CBPD-409), we demonstrate only p300/CBP degradation to completely extinguish its catalytic activity and potently inhibit prostate cancer growth. Here, CREBBP is linked to prostate carcinoma.